MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Functional Activity of Apomorphine Relative to Dopamine at Dopamine Receptors: Findings from G Protein Coupled Receptor Biosensor Assays

    B. Yegla, P. Jenner, M. Grall, J. Rubin (Rockville, USA)

    Objective: Characterize the functional activity of apomorphine relative to dopamine using a modern panel of G protein-coupled receptor biosensor assays. Background: The structural similarity of…
  • 2025 International Congress

    Comparative Safety of Different Routes of Apomorphine Administration in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Al Midani, A. Ahmad, O. Razouk, L. Mohamedali, M. Al Khalidi, B. Al Karam, A. Khater (Sharjah, United Arab Emirates)

    Objective: To assess the safety profiles of inhaled, sublingual, and subcutaneous apomorphine in patients with Parkinson’s disease (PD). Background: Apomorphine is a direct-acting D1/D2 agonist…
  • 2025 International Congress

    Neuroprotection on the Horizon: Are GLP-1 Receptor Agonists the Next Breakthrough in Parkinson’s Disease?

    M. Helal, H. Aboushawareb, O. Hussein Abbas, R. Haddad, Y. Zain, A. S.A Osman, N. Hamam, A. Hassan (Zagazig, Egypt)

    Objective: This meta-analysis evaluates the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with Parkinson’s disease (PD). Background: Epidemiological studies suggest an increased…
  • 2025 International Congress

    Timing And Type Of Adverse Events Following Long-Term Treatment With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) Infusion – Data From The ELEGANCE Interim Analysis

    N. Smith, B. Amlani (Reading, United Kingdom)

    Objective: To evaluate the type and timing of occurrence of treatment-emergent adverse events (AEs) in people with advanced Parkinson’s disease (PD) following up to one…
  • 2025 International Congress

    Multidimensional Assessment of Levodopa/Carbidopa/Entacapone Gel (LECIG) Therapy in Parkinson’s Disease: Perspectives of Patients, Clinicians, and Caregivers

    M. Minar, I. Straka, Z. Andre, M. Grofik, J. Necpal, M. Rusinkova, V. Han, Z. Kosutzka (Bratislava, Slovakia)

    Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months. Background: Advanced PD…
  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    Repetitive Transcranial Magnetic Stimulation For Freezing Of Gait And Motor Function In Parkinson’s Disease: A Systematic Review And Meta-Analysis Of Randomized Controlled Trials

    J. Pitton Rissardo, A. Fornari Caprara (Camden, USA)

    Objective: To evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on motor function, freezing of gait (FOG), and mobility in patients with Parkinson’s disease…
  • 2025 International Congress

    Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease

    JV. Costa, EF. Muricy, FS. Brito, GS. Nunes, SC. Baran, GV. de Vasconcelos, CF. Do Nascimento, NS. Dos Santos, JX. Oliveira, ME. Vassoler, FG. Nascimento, AM. Guerra, RB. Kauark (Salvador, Brazil)

    Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…
  • 2025 International Congress

    Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

    M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

    Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
  • 2025 International Congress

    Positive Relationship Between Improvement in Sleep and Quality of Life During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion

    R. Hauser, A. Videnovic, P. Odin, K. Chaudhuri, M. Shah, J. Homola, L. Bergmann, R. Gupta, O. Vaou (Tampa, USA)

    Objective: To investigate the relationship between improvements in sleep disturbances and quality of life (QoL) in adults with advanced Parkinson’s disease (aPD) treated with a…
  • « Previous Page
  • 1
  • …
  • 310
  • 311
  • 312
  • 313
  • 314
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley